Boston Scientific Corp (BSX) Receives a Buy from Raymond James


In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Boston Scientific Corp (BSX), with a price target of $48.00. The company’s shares closed last Monday at $38.23.

According to TipRanks.com, Bedford is a top 100 analyst with an average return of 15.1% and a 68.6% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Edwards Lifesciences, and Nuvectra Corporation.

Currently, the analyst consensus on Boston Scientific Corp is a Strong Buy with an average price target of $48.69, which is a 27.4% upside from current levels. In a report issued on September 30, Stephens also reiterated a Buy rating on the stock with a $48.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $43.84 and a one-year low of $31.56. Currently, Boston Scientific Corp has an average volume of 5.9M.

Based on the recent corporate insider activity of 158 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts